Interaction Checker

Alosetron interactions

Alosetron (Lotronex) has 88 documented interactions across the FDA labels and fact sheets we index: 11 major, 42 moderate, 3 minor, and 32 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

What Alosetron looks like

All 6 versions
Alosetron 1 mg tablet: blue, oval, 11 mm, imprinted GX on one side and CT1 on the other.
GX / CT1
1 mg · blue · oval · 11 mm
Sebela
Alosetron 0.5 mg tablet: white, oval, 11 mm, imprinted GX on one side and EX1 on the other.
GX / EX1
0.5 mg · white · oval · 11 mm
Sebela
Alosetron 0.5 mg tablet: white, oval, 11 mm, imprinted AN248.
AN248
0.5 mg · white · oval · 11 mm
Amneal
Alosetron 1 mg tablet: blue, oval, 11 mm, imprinted AN249.
AN249
1 mg · blue · oval · 11 mm
Amneal

Renderings from the FDA labels' product listings: color, shape, size, and imprint. 6 documented versions from 6 labelers.

Interactions from the label

Major interactions (11)

  • Cannabidiol (prescription)anticonvulsantMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • CimetidineH2 blockerMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • CiprofloxacinfluoroquinoloneMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • Deferasiroxiron supplementMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • FluvoxamineSSRIMajor

    Concomitant use of fluvoxamine ( 4.3 ) (Alosetron label, Contraindications)

  • LevofloxacinfluoroquinoloneMajor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron label, Drug interactions)

  • MexiletineantiarrhythmicMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • MoxifloxacinfluoroquinoloneMajor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron label, Drug interactions)

  • OfloxacinfluoroquinoloneMajor

    Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (Alosetron label, Drug interactions)

  • Viloxazinenorepinephrine reuptake inhibitorMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

  • ZileutonCYP1A2 inhibitorMajor

    Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (Alosetron label, Contraindications)

Moderate interactions (42)

  • AmiodaroneantiarrhythmicModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • AprepitantCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • AtazanavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • CenobamateanticonvulsantModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Clarithromycinmacrolide antibioticModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • CyclosporineimmunosuppressantModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • DarunavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Darunavir and cobicistatantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Diltiazemcalcium channel blockerModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • DronedaroneantiarrhythmicModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • EfavirenzantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • EluxadolineopioidModerate

    Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (Eluxadoline label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Erythromycinmacrolide antibioticModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • EverolimusimmunosuppressantModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Fluconazoleazole antifungalModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • FosamprenavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • ImatinibCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • IsoniazidantibioticModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Itraconazoleazole antifungalModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Ketoconazoleazole antifungalModerate

    Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (Alosetron label, Drug interactions)

  • LeflunomideimmunosuppressantModerate

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Leflunomide label, Drug interactions)

  • LenacapavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • NefazodoneantidepressantModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • PerampanelanticonvulsantModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Posaconazoleazole antifungalModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • PrimaquineantimalarialModerate

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (Primaquine label, Drug interactions)

  • RanolazineQT-prolonging drugModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • RitonavirantiretroviralModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Suvorexantsedative-hypnoticModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • TeriflunomideimmunosuppressantModerate

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (Teriflunomide label, Drug interactions)

  • Ticagrelorantiplatelet agentModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Verapamilcalcium channel blockerModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

  • Voriconazoleazole antifungalModerate

    CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (Alosetron label, Drug interactions)

Minor mentions (3)

  • HydralazinevasodilatorMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron label, Drug interactions)

  • Isosorbide dinitrate and hydralazinenitrateMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron label, Drug interactions)

  • ProcainamideantiarrhythmicMinor

    Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (Alosetron label, Drug interactions)

No significant interaction reported (32)

  • Allopurinolxanthine oxidase inhibitorNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • AminophyllinemethylxanthineNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Butalbital, acetaminophen, and caffeinebarbiturateNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Butalbital, acetaminophen, caffeine, and codeinebarbiturateNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Butalbital, aspirin, and caffeinebarbiturateNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Butalbital, aspirin, caffeine, and codeinebarbiturateNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Conjugated estrogensestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Conjugated estrogens and bazedoxifeneestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Desogestrel and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Drospirenone and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Ergotamine and caffeineergot alkaloidNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • Esterified estrogens and methyltestosteroneestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • EstradiolestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Estradiol and dienogestoral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Estradiol and norethindroneestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Etonogestrel and ethinyl estradiolestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Febuxostatxanthine oxidase inhibitorNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • FulvestrantestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • LevonorgestrelprogestinNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • MedroxyprogesteroneprogestinNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • MegestrolprogestinNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Norelgestromin and ethinyl estradiolestrogenNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • NorethindroneprogestinNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Norethindrone and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Norgestimate and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Norgestrel and ethinyl estradioloral contraceptiveNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • Orphenadrine, aspirin, and caffeinemuscle relaxantNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • PentoxifyllinemethylxanthineNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

  • ProgesteroneprogestinNo interaction

    Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (Alosetron label, Drug interactions)

  • TheophyllinemethylxanthineNo interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (Alosetron label, Drug interactions)

Check Alosetron against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.